EUVIMEDEUVIMED entdecken
Open Access

Harnessing mRNA-encoded PcrV-targeting monoclonal antibodies for combating antibiotic-resistant P. aeruginosa infections

Xingyun Wang, Xingyue Gao, Cong Liu, Liang Yang, Liang Li, Nino Rcheulishvili, Ziqian Wang, Jiubiao Guo, Chuanlan Yang, Yueling Zheng, Xuehua Pan, Peng George Wang und 1 weitere

Molecular Therapy · 2025-12 · 33 (12) · 6265-6281

DOI: 10.1016/j.ymthe.2025.09.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-12. Verfasst von Xingyun Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Homeostatic Medicine Institute, Southern University of Science and Technology, Shenzhen 518055, China. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Antibodies, Monoclonal, Pseudomonas Infections, RNA, Messenger. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shenzhen Municipal Fundamental Research Program, Science, Technology and Innovation Commission of Shenzhen Municipality, Guangdong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rising prevalence of antibiotic resistance, particularly among Pseudomonas aeruginosa strains, has become a substantial threat to public health. There is an urgent need for new therapeutics to tackle this challenge. This study explores the potential of mRNA-encoded monoclonal antibodies (mAbs) targeting the type III secretion system protein V (PcrV) antigen as a strategy to combat P. aeruginosa infections. We derived anti-PcrV mAbs from the B cells of immunized mice and identified two potent mAbs, M2C10 and M4C12, with the strongest binding affinity to PcrV. These mAbs were expressed, purified to high homogeneity, and encoded into mRNA for in vitro and in vivo functional assays. The results indicated that both mAbs exhibit high antibacterial activity in vitro. For in vivo efficacy, specific pathogen-free male BALB/c mice were used in acute systemic and pneumonia models. Survival, tissue bacterial loads, and histopathology were assessed. M2C10-mRNA outperformed M4C12-mRNA in increasing the survival rate of challenged mice, reducing tissue bacterial loads, and protecting against tissue damage in a murine model of acute infection. Collectively, our findings indicate that mRNA-encoded mAbs, particularly M2C10, offer a promising therapeutic strategy against P. aeruginosa, potentially serving as an alternative to conventional antibiotics and warrant further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAntibodies, MonoclonalPseudomonas InfectionsRNA, MessengerAntigens, BacterialType III Secretion SystemsDrug Resistance, BacterialAnimalsMiceDisease Models, AnimalAnti-Bacterial AgentsHumansMaleMice, Inbred BALB CMicrobial Sensitivity TestsBacterial ToxinsPore Forming Cytotoxic Proteins

Stichwörter der Autor:innen

PcrVPseudomonas aeruginosaantibacterial mAbsantibiotic resistancebacterial infectionimmunotherapymRNA

Substanzen

Antibodies, MonoclonalRNA, Messengerantigen V, PseudomonasAntigens, BacterialAnti-Bacterial AgentsType III Secretion SystemsBacterial ToxinsPore Forming Cytotoxic Proteins

Autor:innen und Institutionen

  • Department of Pharmacology, School of Medicine, Homeostatic Medicine Institute, Southern University of Science and Technology, Shenzhen 518055, China.
  • Department of Pharmacology, School of Medicine, Homeostatic Medicine Institute, Southern University of Science and Technology, Shenzhen 518055, China; Institute of Microbiology, Chinese Academy of Sciences, Beijing 1001…
  • Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China. Electronic address: pxh0209@163.com.
  • Department of Pharmacology, School of Medicine, Homeostatic Medicine Institute, Southern University of Science and Technology, Shenzhen 518055, China; Pengbo Biotechnology Company, Shenzhen, China. Electronic address: w…
  • Department of Pharmacology, School of Medicine, Homeostatic Medicine Institute, Southern University of Science and Technology, Shenzhen 518055, China. Electronic address: heyj@sustech.edu.cn.

Förderung

  • Shenzhen Municipal Fundamental Research Program
  • Science, Technology and Innovation Commission of Shenzhen Municipality
  • Guangdong Provincial Natural Science Foundation
  • National Key Research and Development Program of China
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Wang, X., Gao, X., Liu, C., Yang, L., Li, L., Rcheulishvili, N., Wang, Z., Guo, J., Yang, C., Zheng, Y., Pan, X., Wang, P. G., & He, Y. (2025). Harnessing mRNA-encoded PcrV-targeting monoclonal antibodies for combating antibiotic-resistant P. aeruginosa infections. Molecular Therapy, 33(12), 6265-6281. https://doi.org/10.1016/j.ymthe.2025.09.025

Vancouver

Wang X, Gao X, Liu C, Yang L, Li L, Rcheulishvili N, et al. Harnessing mRNA-encoded PcrV-targeting monoclonal antibodies for combating antibiotic-resistant P. aeruginosa infections. Molecular Therapy. 2025;33(12):6265-6281. doi:10.1016/j.ymthe.2025.09.025

BibTeX
@article{Wang2025,
  author = {Wang, Xingyun and Gao, Xingyue and Liu, Cong and Yang, Liang and Li, Liang and Rcheulishvili, Nino and Wang, Ziqian and Guo, Jiubiao and Yang, Chuanlan and Zheng, Yueling and Pan, Xuehua and Wang, Peng George and He, Yunjiao},
  title = {Harnessing mRNA-encoded PcrV-targeting monoclonal antibodies for combating antibiotic-resistant P. aeruginosa infections},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {12},
  pages = {6265--6281},
  doi = {10.1016/j.ymthe.2025.09.025}
}
Kostenlos starten →